Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future

Table 2 Summary of treatment in severe acute respiratory syndrome coronavirus-2 negative patients with stable inflammatory bowel disease disease course

Drug	Suggestions	Additional comments
	Continue therapy
Salicylates	Yes	Data from the SECURE-IBD of possible harm need to be confirmed.
Locally acting steroids	Yes	No specific data available
Systemic steroids	Yes	Limit use to strictly necessary and taper rapidly
Azathioprine	Yes	Data from the SECURE-IBD of possible harm need to be confirmed, the risk of reactivation seems to outweigh the risk of continued treatment
Methotrexate	Yes	Limited data available
Anti-TNF	Yes	Data from the SECURE-IBD indicate better outcomes compared to other treatments; there are ongoing trials for the treatment of COVID-19
Vedolizumab, anti-IL-12/23	Yes	Limited data available
Tofacitinib	Yes	Limited data available

COVID-19: Coronavirus disease 2019; IBD: Inflammatory bowel diseases; IL: Interleukin; TNF: Tumor necrosis factors.